ZIOPHARM Oncology (NASDAQ:ZIOP) Trading 8.3% Higher

Share on StockTwits

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares traded up 8.3% on Wednesday . The company traded as high as $4.70 and last traded at $4.55, 2,295,300 shares were traded during trading. An increase of 33% from the average session volume of 1,720,666 shares. The stock had previously closed at $4.20.

A number of research analysts recently weighed in on the stock. Zacks Investment Research raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, October 12th. ValuEngine lowered shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 2nd. HC Wainwright reissued a “buy” rating and set a $6.50 price target on shares of ZIOPHARM Oncology in a research report on Wednesday, October 2nd. BidaskClub raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, October 29th. Finally, Raymond James set a $6.50 price target on shares of ZIOPHARM Oncology and gave the company an “outperform” rating in a research report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $6.25.

The firm has a market cap of $803.77 million, a P/E ratio of -9.48 and a beta of 2.60. The company has a quick ratio of 10.34, a current ratio of 10.34 and a debt-to-equity ratio of 0.01. The firm’s 50-day simple moving average is $4.23 and its 200 day simple moving average is $4.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.34). As a group, analysts forecast that ZIOPHARM Oncology Inc. will post -0.36 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. raised its position in ZIOPHARM Oncology by 24.3% in the second quarter. BlackRock Inc. now owns 11,753,413 shares of the biotechnology company’s stock worth $68,522,000 after acquiring an additional 2,294,498 shares during the period. Vanguard Group Inc. raised its position in ZIOPHARM Oncology by 11.6% in the second quarter. Vanguard Group Inc. now owns 11,254,728 shares of the biotechnology company’s stock worth $65,615,000 after acquiring an additional 1,167,963 shares during the period. Northern Trust Corp raised its position in ZIOPHARM Oncology by 3.0% in the second quarter. Northern Trust Corp now owns 1,716,285 shares of the biotechnology company’s stock worth $10,007,000 after acquiring an additional 49,939 shares during the period. Morgan Stanley raised its position in ZIOPHARM Oncology by 13.2% in the second quarter. Morgan Stanley now owns 1,385,120 shares of the biotechnology company’s stock worth $8,075,000 after acquiring an additional 161,833 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in ZIOPHARM Oncology by 7.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 898,615 shares of the biotechnology company’s stock worth $5,239,000 after acquiring an additional 63,762 shares during the period. 38.58% of the stock is currently owned by institutional investors and hedge funds.

ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

See Also: Quick Ratio

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.